Ion Exchange (India) Limited reported a significant contraction in profitability for the first quarter of FY26, with standalone net profit after tax (PAT) falling 75.7% year-on-year to ₹11.40 crore. The company's consolidated PAT dropped sharply to ₹3.06 crore, compared to ₹48.44 crore in Q1FY25, reflecting severe margin pressure and higher operational costs. The results were approved by the Board of Directors on August 5, 2026.

Key Financial Metrics

The latest quarterly results reveal a stark divergence between revenue growth and profitability. While consolidated revenue from operations rose 20.1% year-on-year to ₹700.46 crore, earnings metrics deteriorated sharply across the board. The following table summarises the key consolidated performance indicators:

The EBITDA contraction to ₹31.70 crore from ₹62.50 crore underscores the depth of margin erosion during the quarter. The EBITDA margin nearly halved to 4.53% from 10.72% in Q1FY25, pointing to a significant rise in operating costs relative to revenue. Finance costs rose substantially to ₹8.21 crore on a standalone basis from ₹1.66 crore in Q1FY25, while consolidated finance costs more than tripled to ₹8.95 crore from ₹2.56 crore, further weighing on the bottom line. Other income also decreased to ₹13.24 crore from ₹19.52 crore, with total standalone income reaching ₹64.88 crore. The decline in standalone profit before tax and exceptional items to ₹15.37 crore from ₹63.04 crore in Q1FY25 further reflects the operational challenges faced during the quarter.

Segment Performance

The company realigned its segment reporting structure effective April 1, 2026, renaming its Engineering segment into Treatment Solutions, Industrial Products, and Lifecycle Services. The table below presents the standalone segment-wise revenue and results:

Treatment Solutions emerged as the largest revenue contributor at ₹201.00 crore but reported a loss of ₹18.26 crore, reversing a profit of ₹18.34 crore in Q1FY25. Specialty Chemicals remained the most profitable segment with a result of ₹24.76 crore, though down from ₹41.11 crore in the prior year. Industrial Products saw revenue growth to ₹105.53 crore from ₹88.45 crore, with results improving to ₹13.66 crore from ₹4.64 crore.

Regulatory and Legal Updates

The auditor's report included an Emphasis of Matter regarding subsidiary Ion Exchange Enviro Farms Limited (IEEFL). SEBI had directed IEEFL to deposit ₹22.02 crore towards investor repayment following a forensic audit. IEEFL has appealed this order before the Securities Appellate Tribunal (SAT), where the next hearing is scheduled for August 12, 2026. During the October 2024 hearing, SEBI's counsel stated that no recovery proceedings would be initiated until the next hearing date. The company does not envisage any liability on this account pending the final outcome.

Deloitte Haskins & Sells LLP reviewed the interim financial statements, confirming compliance with Ind AS 34 and SEBI Listing Regulations. The results include unreviewed financial information from certain subsidiaries and associates, which management deemed immaterial to the group's overall performance.

Ion Exchange (India) Ltd has secured an international contract worth USD 52.83 million (approximately INR 500 crore) from Hyundai Engineering & Construction Co., Ltd. for the supply of filtration units in the Middle East. The project is scheduled to be executed over a period of 18 months, representing a significant expansion in the company's overseas order book.

Order Details

The order involves the supply of filtration units awarded by Hyundai Engineering & Construction Co., Ltd., an international entity. The disclosure was made to the stock exchanges pursuant to Regulation 30(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The following table summarises the key details of the contract:

Compliance and Disclosures

The company confirmed that the promoter, promoter group, or group companies do not have any interest in the entity that awarded the order. Furthermore, the transaction does not fall within related party transactions. The execution timeline is set at 18 months from the commencement of the project. The filing was signed by Nikisha Solanki, Company Secretary & Compliance Officer of Ion Exchange (India) Ltd.